What is a stock summary page? Click here for an overview.
Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Share Class Description:
SRPT: Ordinary SharesCompare
Compare
Traded in other countries / regions
SRPT.USASRPT.Mexico0L35.UKS1RP34.BrazilAB3A.Germany Index Membership
Russell 1000Russell 3000 IPO Date
1997-06-04Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.01 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.88 | |||||
| Debt-to-EBITDA | 4.24 | |||||
| Interest Coverage | 11.86 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.69 | |||||
| Beneish M-Score | -1.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.9 | |||||
| 3-Year FCF Growth Rate | 18.1 | |||||
| 3-Year Book Growth Rate | 14 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 63.37 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 30.82 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.86 | |||||
| 9-Day RSI | 28.22 | |||||
| 14-Day RSI | 29.25 | |||||
| 3-1 Month Momentum % | -12.26 | |||||
| 6-1 Month Momentum % | -14.18 | |||||
| 12-1 Month Momentum % | -16.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.2 | |||||
| Quick Ratio | 3.18 | |||||
| Cash Ratio | 1.85 | |||||
| Days Inventory | 571.48 | |||||
| Days Sales Outstanding | 83.5 | |||||
| Days Payable | 159.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | -0.24 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.22 | |||||
| Operating Margin % | 11.47 | |||||
| Net Margin % | 12.37 | |||||
| FCF Margin % | -18.55 | |||||
| ROE % | 20.83 | |||||
| ROA % | 6.73 | |||||
| ROIC % | 11.1 | |||||
| 3-Year ROIIC % | 45.3 | |||||
| ROC (Joel Greenblatt) % | 26.44 | |||||
| ROCE % | 9.9 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.29 | |||||
| Forward PE Ratio | 8.37 | |||||
| PE Ratio without NRI | 26.75 | |||||
| PS Ratio | 4.34 | |||||
| PB Ratio | 4.67 | |||||
| Price-to-Tangible-Book | 4.75 | |||||
| EV-to-EBIT | 25.54 | |||||
| EV-to-Forward-EBIT | 4.57 | |||||
| EV-to-EBITDA | 22.5 | |||||
| EV-to-Forward-EBITDA | 4.41 | |||||
| EV-to-Revenue | 3.75 | |||||
| EV-to-Forward-Revenue | 2.24 | |||||
| EV-to-FCF | -20.22 | |||||
| Price-to-GF-Value | 0.43 | |||||
| Price-to-Median-PS-Value | 0.18 | |||||
| Price-to-Graham-Number | 2.05 | |||||
| Price-to-Net-Current-Asset-Value | 11.19 | |||||
| Earnings Yield (Greenblatt) % | 3.92 | |||||
| FCF Yield % | -4.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SRPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,901.979 | ||
| EPS (TTM) ($) | 2.28 | ||
| Beta | 0.76 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 0.59 | ||
| Volatility % | 30.31 | ||
| 14-Day RSI | 29.25 | ||
| 14-Day ATR ($) | 5.472193 | ||
| 20-Day SMA ($) | 94.2545 | ||
| 12-1 Month Momentum % | -16.41 | ||
| 52-Week Range ($) | 72.17 - 173.25 | ||
| Shares Outstanding (Mil) | 97.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(SRPT)'s stock price today?
The current price of SRPT is $73.61. The 52 week high of SRPT is $173.25 and 52 week low is $72.17.
When is next earnings date of Sarepta Therapeutics Inc(SRPT)?
The next earnings date of Sarepta Therapeutics Inc(SRPT) is 2025-05-01 Est..
Does Sarepta Therapeutics Inc(SRPT) pay dividends? If so, how much?
Sarepta Therapeutics Inc(SRPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers